Status and phase
Conditions
Treatments
About
A phase I clinical trial evaluating the safety, tolerability, pharmacokinetics, and initial efficacy of HLX208 (BRAF V600E inhibitor) in combination with trametinib in patients with advanced solid tumors
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
220 participants in 4 patient groups
Loading...
Central trial contact
Guo ye, PI; Zhang Li, leading PI
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal